Sirtuin-2, NAD-Dependent Deacetylase, Is a New Potential Therapeutic Target for HIV-1 Infection and HIV-Related Neurological Dysfunction
Clara Duran-Castells, Anuska Llano, Ai Kawana‐Tachikawa, Anna Prats, Ignacio Martínez‐Zalacaín, Mie Kobayashi‐Ishihara, Bruna Oriol-Tordera, Ruth Peña, Cristina Gálvez, Sandra Silva-Arrieta, Bonaventura Clotet, Eva Riveira‐Muñoz, Esther Ballana, Júlia G. Prado, Javier Martínez‐Picado, Jorge Sánchez, Beatriz Mothe, Dennis J. Hartigan-O’Connor, Tony Wyss‐Coray, Andreas Meyerhans, Magnus Gisslén, Richard W. Price, Carles Soriano‐Mas, José A. Muñoz-Moreno, Christian Brander, Marta Ruiz‐Riol
Abstract
Neurocognitive disorders are frequently reported in people living with HIV (PLWH) even with the introduction of combined antiretroviral treatment (cART). To identify biomarkers and potential therapeutic tools to target HIV infection in peripheral blood and in the central nervous system (CNS), plasma proteomics were applied in untreated chronic HIV-infected individuals with different levels of virus control.